Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials
Although vemurafenib showed efficacy in metastatic melanoma, off-label use resulted in limited benefit and increased adverse events. Unclear endpoints and underreported adverse events highlight the need for improved clinical trial design.
Authors
- Brooke M. Gardner (ORCID: https://orcid.org/0000-0001-7999-8827)
- Vinay Prasad (ORCID: https://orcid.org/0000-0002-6110-8221)
- Andriana Peña (ORCID: https://orcid.org/0000-0001-6760-4640)
- Taylor Gardner (ORCID: https://orcid.org/0000-0002-7505-4092)
- Jordan Tuia (ORCID: https://orcid.org/0000-0001-7341-0279)
- Kelsey Snider (ORCID: https://orcid.org/0000-0003-2570-3573)
- Ryan Ottwell (ORCID: https://orcid.org/0000-0002-6574-2844)
- Jacob Duncan (ORCID: https://orcid.org/0000-0002-0990-0406)
- Matt Vassar (ORCID: https://orcid.org/0000-0003-2859-6152)
- Griffin Hughes (ORCID: https://orcid.org/0000-0003-3863-7915)
- Alyson Haslam (ORCID: https://orcid.org/0000-0002-7876-3978)
- Ryan McIntire (ORCID: https://orcid.org/0000-0002-1447-3832)
- Chase Ladd (ORCID: https://orcid.org/0000-0003-3789-7299)
Institutions
- University of California, San Francisco (US)
- Oklahoma State University Center for Health Sciences (US)
Publication Details
- Journal
- Melanoma Management
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1080/20450885.2025.2463830
- Citations
- 2
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Health Sciences Center New Orleans, Louisiana State University
- Arnold Ventures
- Johns Hopkins University Press
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Drug Abuse